Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer

Colorectal cancer (metastatic) - bevacizumab: letter from the Department of Health

In March 2010, the Department of Health confirmed that the amendment to the Patient Access Scheme can be considered by NICE.

This page was last updated: 19 August 2010